Difference between revisions of "ENST00000444042.2"
| (7 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | ''CYP4A22-AS1'', Long non-coding RNA with enhancer-like function in human | |
==Annotated Information== | ==Annotated Information== | ||
| − | === | + | ===Approved Symbol=== |
| − | + | ''CYP4A22-AS1'' | |
| + | ===Approved Name=== | ||
| + | ''CYP4A22-AS1'': CYP4A22 Antisense RNA 1 | ||
| + | NcRNA-A3 | ||
| + | |||
| + | ===Characteristics=== | ||
| + | ''CYP4A22-AS1'' gene is Spliced, up to 4 exons, ~920 nt transcript.Its loci covers ~ 80kb and is antisense to CYP4A22 and CYP4Z1.<ref name="ref1" /> | ||
| + | ''CYP4A22-AS1'' is transcribed bidirectionally, downstream from TAL1 and PDZK1IP1 on same strand.<ref name="ref1" /> | ||
| + | In-vitro translation of ''CYP4A22-AS1'' showed no sign of protein product.<ref name="ref1" /> | ||
===Function=== | ===Function=== | ||
| − | + | ''CYP4A22-AS1'' expression stimulates TAL1 gene expression (in MCF7 cells).<ref name="ref1" /> | |
===Regulation=== | ===Regulation=== | ||
Please input regulation information here. | Please input regulation information here. | ||
| + | |||
| + | ===Disease=== | ||
| + | Please input disease information here. | ||
===Expression=== | ===Expression=== | ||
| − | + | Expressed and functionally of ''CYP4A22-AS1'' characterized in MCF7 cells. <ref name="ref1" /> | |
| − | + | ''CYP4A22-AS1'' identified as enriched in K562, HelaS3 and HepG2 nuclear fractions. <ref name="ref2" /> | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
| − | + | *The Wistar Institute, 3601 Spruce Street, Philadelphia | |
| + | *Centre for Genomic Regulation (CRG), UPF, Barcelona, Spain | ||
==References== | ==References== | ||
| − | + | <references> | |
| − | + | <ref name="ref1"> Derrien T & Guigo R. Long non-coding RNAs with enhancer-like function in human cells[J]. M S-Med Sci. 2011, 27(4):359-361 </ref>(1) | |
| − | + | <ref name="ref2"> Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression[J]. Genome Res. 2012, 22(9):1775-1789 | |
| − | + | </ref>(2) | |
| − | + | </references> | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | </ | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ===Sequence=== | |
| − | + | Please input sequence here. | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Latest revision as of 06:02, 22 November 2018
CYP4A22-AS1, Long non-coding RNA with enhancer-like function in human
Contents
Annotated Information
Approved Symbol
CYP4A22-AS1
Approved Name
CYP4A22-AS1: CYP4A22 Antisense RNA 1 NcRNA-A3
Characteristics
CYP4A22-AS1 gene is Spliced, up to 4 exons, ~920 nt transcript.Its loci covers ~ 80kb and is antisense to CYP4A22 and CYP4Z1.[1] CYP4A22-AS1 is transcribed bidirectionally, downstream from TAL1 and PDZK1IP1 on same strand.[1] In-vitro translation of CYP4A22-AS1 showed no sign of protein product.[1]
Function
CYP4A22-AS1 expression stimulates TAL1 gene expression (in MCF7 cells).[1]
Regulation
Please input regulation information here.
Disease
Please input disease information here.
Expression
Expressed and functionally of CYP4A22-AS1 characterized in MCF7 cells. [1] CYP4A22-AS1 identified as enriched in K562, HelaS3 and HepG2 nuclear fractions. [2]
Labs working on this lncRNA
- The Wistar Institute, 3601 Spruce Street, Philadelphia
- Centre for Genomic Regulation (CRG), UPF, Barcelona, Spain
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Derrien T & Guigo R. Long non-coding RNAs with enhancer-like function in human cells[J]. M S-Med Sci. 2011, 27(4):359-361
- ↑ Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression[J]. Genome Res. 2012, 22(9):1775-1789
Sequence
Please input sequence here.
